We use Pittsburgh compound B to illustrate some of the critical steps in developing a potent and selective Aβ PET imaging agent.
(1′S*,2′S* --6-Nor-2′,3′-dihydro-4′-deoxo-ABA (2) was designed and synthesized as a candidate lead compound for developing a potent and specific inhibitor of ABA 8′-hydroxylase.
We have used structure-based drug design in conjunction with kinome profiling and cellular assays to develop a potent, selective, and irreversible BTK kinase inhibitor, QL47, which covalently modifies Cys481.
In this letter we describe how we modified substitution around this pharmacophore to develop a potent, selective and orally active renin inhibitor.
113 Their search was initiated by a high-throughput screen of their compound library followed by optimization of their lead structure to develop a potent, selective, and orally-available compound, (2E -3- 4- [2,4-bis trifluoromethyl benzyl] oxy)-3-methoxyphenyl)-2E -3- 4- [2,4-bis trifluoromethyl benzyladiazol-2E -3- 4- [2,4-bis trifluoromethyl benzyl
By optimizing substituents on the benzimidazole core part of the lead compound 5a, we were able to develop a potent, orally available, and brain-penetrable Y5 selective antagonist (5k).
Here, we utilized the helix12 (H12 -folding inH12 -foldingothesinhibitionbination withypothesisinusly determined X-ray combinationucture of PPARγ agonist MEKT-21 (6) complexed with the PPARγ ligand-binding dourin, to design and developreviously phenylalkynyl amideterminedARγ antagonist 9i, focusing initially on pinpoint structural modification of the propanoic acid moiety of 6.
Further the predicted R326H and R356Q mutations can be further studied by wet lab scientist to investigate the evidence of Tyrp1 protein mutation in association to OCA3 and develop a potent drug target for OCA3.
In the current study, to elicit a more robust immune response and develop a potent vaccination strategy against trichinellosis, a heterologous prime-boost vaccination regimen for Ts87 was used in mice and the protective efficacy was evaluated compared to the homologous DNA prime-boost or protein prime-boost immunization alone.
MDS' ultimate goal is to develop a potent cancer drug.
